Patents by Inventor Jeffrey Way
Jeffrey Way has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220282263Abstract: Provided herein are methods of generating engineered organisms with targeted genome designs, such as recoding designs, and targeted functional properties. Also provided are methods of generating biomanufacturing engineered organisms and uses thereof for production of biomanufactured products.Type: ApplicationFiled: May 14, 2020Publication date: September 8, 2022Inventors: Ryan Gallagher, Alexis Rovner, George Church, Jeffrey Way, Pamela Silver
-
Publication number: 20220228104Abstract: Provided herein are engineered organism containing a transgene in which expression of the transgene in an open environment is prevented or reduced, for example, by recoding designs. Also provided are methods of producing such engineered organism and use of such engineered organisms as therapeutics or for producing food, food supplement, and animal feed products.Type: ApplicationFiled: May 14, 2020Publication date: July 21, 2022Inventors: Ryan Gallagher, Alexis Rovner, George Church, Jeffrey Way, Pamela Silver
-
Publication number: 20150141626Abstract: Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.Type: ApplicationFiled: January 2, 2015Publication date: May 21, 2015Inventors: Stephen D. Gillies, Jeffrey Way, Anita A. Hamilton
-
Patent number: 8926973Abstract: Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.Type: GrantFiled: May 26, 2011Date of Patent: January 6, 2015Assignee: Merck Patent GmbHInventors: Stephen D. Gillies, Jeffrey Way, Anita A. Hamilton
-
Patent number: 8536308Abstract: The present invention provides an isolated IL-6 antagonist including an antibody variable region that prevents IL-6 from binding to gp130. The present invention also provides compositions and methods for treating IL-6 related diseases based on the IL-6 antagonists of the invention.Type: GrantFiled: July 12, 2010Date of Patent: September 17, 2013Assignee: Merck Patent GmbHInventors: Jeffrey Way, Yuan Liu
-
Publication number: 20120309936Abstract: Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.Type: ApplicationFiled: May 26, 2011Publication date: December 6, 2012Applicant: Merck Patent GmbHInventors: Stephen D. Gillies, Jeffrey Way, Anita A. Hamilton
-
Patent number: 8066994Abstract: Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more than one type of antibody and/or mutant antibody sequences. Hybrid antibody fusion proteins of the invention may be produced at high levels and may combine functional properties characteristic of different antibody types in addition to functional properties of a non-antibody moiety.Type: GrantFiled: July 19, 2006Date of Patent: November 29, 2011Assignee: Merck Patent GmbHInventors: Stephen D. Gillies, Jeffrey Way, Kin-Ming Lo
-
Patent number: 7973150Abstract: Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.Type: GrantFiled: September 1, 2009Date of Patent: July 5, 2011Assignee: Merck Patent GmbHInventors: Stephen D. Gillies, Jeffrey Way, Anita A. Hamilton
-
Publication number: 20110038877Abstract: The present invention provides an isolated IL-6 antagonist including an antibody variable region that prevents IL-6 from binding to gp130. The present invention also provides compositions and methods for treating IL-6 related diseases based on the IL-6 antagonists of the invention.Type: ApplicationFiled: July 12, 2010Publication date: February 17, 2011Applicant: Merck Patent GmbHInventors: Jeffrey Way, Stephen D. Gillies, Kin-Ming Lo, Yuan Liu
-
Patent number: 7820155Abstract: The present invention provides an isolated IL-6 antagonist including an antibody variable region that prevents IL-6 from binding to gp130. The present invention also provides compositions and methods for treating IL-6 related diseases based on the IL-6 antagonists of the invention.Type: GrantFiled: December 29, 2006Date of Patent: October 26, 2010Assignee: Merck Patent GmbHInventor: Jeffrey Way
-
Publication number: 20100016562Abstract: Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.Type: ApplicationFiled: September 1, 2009Publication date: January 21, 2010Inventors: Stephen D. Gillies, Jeffrey Way, Anita A. Hamilton
-
Patent number: 7601814Abstract: Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.Type: GrantFiled: September 23, 2005Date of Patent: October 13, 2009Assignee: Merck Patent GmbHInventors: Stephen D. Gillies, Jeffrey Way, Anita A. Hamilton
-
Patent number: 7589179Abstract: Modified interleukin-7 (IL-7) polypeptides are disclosed. The modified IL-7 polypeptides have alterations to one or more potential T-cell epitopes, thereby to reduce a T-cell response.Type: GrantFiled: December 8, 2005Date of Patent: September 15, 2009Assignee: Merck Patent GmbHInventors: Stephen D. Gillies, Jeffrey Way
-
Publication number: 20070274991Abstract: The invention discloses methods of treatment of tumors that express oncogenic forms of the epidermal growth factor receptor (EGFR), such as EGFRvIII. The methods include testing of cancer patients for expression of EGFRvIII in their tumors, followed by treatment with a protein that contains antibody variable regions that recognize specific epitopes on the surface of the EGFR.Type: ApplicationFiled: March 29, 2007Publication date: November 29, 2007Inventors: Jeffrey Way, Ginger Chao, Catherine Cresson, Douglas Lauffenburger, K. Wittrup
-
Publication number: 20070269435Abstract: The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules.Type: ApplicationFiled: March 12, 2007Publication date: November 22, 2007Inventors: Stephen Gillies, Francis Carr, Jones Tim, Graham Carter, Anila Hamilton, Stephen Williams, Marian Hanlon, John Watkins, Matthew Baker, Jeffrey Way
-
Publication number: 20070178098Abstract: The present invention provides an isolated IL-6 antagonist including an antibody variable region that prevents IL-6 from binding to gp130. The present invention also provides compositions and methods for treating IL-6 related diseases based on the IL-6 antagonists of the invention.Type: ApplicationFiled: December 29, 2006Publication date: August 2, 2007Applicant: Merck Patent GmbHInventors: Jeffrey Way, Stephen Gillies, Kin-Ming Lo, Yuan Liu
-
Patent number: 7211253Abstract: The invention relates to novel modified erythropoietin (EPO) forms such as fusion proteins comprising a Fc portion of an Ig molecule and a target molecule having the biological activity of EPO. By selective altering of the amino acid sequences of the erythropoietin moiety as well as of the immunoglobulin moiety and the glycosylation pattern of erythropoietin fusion proteins with enhanced biological activity can be obtained. The invention relates also to novel nun-fused EPO molecules which have a pattern of cysteines or disulfide bonding which is distinct from human or animal EPO.Type: GrantFiled: November 9, 2000Date of Patent: May 1, 2007Assignee: Merck Patentgesellschaft Mit Beschrankter HaftungInventor: Jeffrey Way
-
Publication number: 20060263856Abstract: Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more than one type of antibody and/or mutant antibody sequences. Hybrid antibody fusion proteins of the invention may be produced at high levels and may combine functional properties characteristic of different antibody types in addition to functional properties of a non-antibody moiety.Type: ApplicationFiled: July 19, 2006Publication date: November 23, 2006Applicant: EMD Lexigen Research Center Corp.Inventors: Stephen Gillies, Jeffrey Way, Kin-Ming Lo
-
Publication number: 20060141581Abstract: Modified interleukin-7 (IL-7) polypeptides are disclosed. The modified IL-7 polypeptides have alterations to one or more potential T-cell epitopes, thereby to reduce a T-cell response.Type: ApplicationFiled: December 8, 2005Publication date: June 29, 2006Applicant: Merck Patent GmbHInventors: Stephen Gillies, Jeffrey Way
-
Publication number: 20060025573Abstract: Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.Type: ApplicationFiled: September 23, 2005Publication date: February 2, 2006Applicant: MERCK Patent GmbHInventors: Stephen Gillies, Jeffrey Way, Anita Hamilton